SCHEMBL3011204

SCHEMBL3011204

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4ccc(F)cc4)CC3)n2)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
USP2 O75604 2/20 0.56
HSD17B10 Q99714 2/20 0.56
RECQL P46063 1/20 0.56
ALDH1A1 P00352 4/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
KDM4E B2RXH2 3/20 0.55
PKM P14618 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.54
GAA P10253 1/20 0.48
HTT P42858 2/20 0.46
LMNA P02545 2/20 0.46
TSHR P16473 2/20 0.46
MAPK1 P28482 2/20 0.46
GLA P06280 1/20 0.46
POLB P06746 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HDAC3 O15379 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013884 0.92 TSHR (0.53) MAPTUSP2HSD17B10RECQLALDH1A1
SCHEMBL3011233 0.92 ALDH1A1 (0.49) MAPTUSP2HSD17B10RECQLALDH1A1
SCHEMBL3007522 0.91 TSHR (0.45) MAPTUSP2HSD17B10RECQLALDH1A1
SCHEMBL3007865 0.91 GAA (0.49) MAPTUSP2HSD17B10RECQLALDH1A1
SCHEMBL3007158 0.91 MAPT (0.56) MAPTUSP2HSD17B10RECQLALDH1A1
SCHEMBL3004835 0.91 HDAC3 (0.47) MAPTUSP2HSD17B10RECQLALDH1A1
SCHEMBL3001739 0.90 MEN1 (0.53) MAPTUSP2HSD17B10RECQLALDH1A1
SCHEMBL3006268 0.89 PKM (0.47) MAPTUSP2HSD17B10RECQLALDH1A1
SCHEMBL3014708 0.89 PKM (0.51) MAPTUSP2HSD17B10RECQLALDH1A1
SCHEMBL3015597 0.89 HSD11B1 (0.47) MAPTUSP2HSD17B10RECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885HSD17B10 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.